Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
News
News | November 17, 2022
Conventional genetic testing for thalassemia requires the use of several techniques, leading to long turnaround times. The single-tube NGS solution from Devyser can replace all these methods and provide the full information needed for a complete genetic profile within a day. This reduces the time of the laboratory workflow by weeks and the complete clinical workflow by up to a month.
Dr. Thessalia Papasavva at the Cyprus Institute of Neurology and Genetics is performing genetic testing for thalassemia in Cyprus, both for diagnostics and as part of the national screening programs. She has pioneered next-generation genetic testing for Thalassemia by fully implementing the NGS solution in their routine lab. She will share her experiences in this webinar.
During the webinar we will discuss:
Webinar details
Date: Tuesday, November 29th, 2022
Time: 10-10:30 am CET I 10-10:30 am PT
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More